High mupirocin susceptibility in isolates of Staphylococcus aureus colonizing hemodialysis patients in a dialysis unit at Medellín
DOI:
https://doi.org/10.17533/udea.iatreia.71Keywords:
dialysis, mupirocin, Staphylococcus aureusAbstract
Objective: To describe the resistance percentage to mupirocin and other antibiotics in Staphylococcus aureus isolates colonizing hemodialysis patients.
Methods: A descriptive study was conducted at an outpatient dialysis center in Medellín and hemodialysis patients with catheter were included. Colonization by S. aureus was evaluated in nostrils and skin. Bacterial identification was performed by PCR and antibiotic susceptibility was determined by the Vitek-2 automated system and by E-test. Clinical information was obtained from medical records.
Results: Two hundred and ten patients were included, of which 50.5% (n=106) were women, with a median for the age of 62 years (IQR 51,87-71,13). Among the clinical characteristics, the frequent use of antibiotics 59% (n=124) and the history of hospitalization 69% (n=145) were highlighted. The percentage of colonization by S. aureus was 33.8% (n=71) and the most frequent site of colonization was nostrils (19%; n=40). All isolates were susceptible to mupirocin by the method of Vitek-2. However, one isolate showed low level resistance to mupirocin by E-test. Colonization by methicillin-resistant isolates (MRSA) was 4.8% (n=10); which presented mainly resistance only to oxacillin (58,3%; n = 7).
Conclusion: The high susceptibility to mupirocin in isolates of colonizing S. aureus suggests its use as rophylactic therapy in hemodialysis patients with high risk of infection. It is important to strengthen programs for the rational use of antibiotics to prevent the spread of mechanisms of resistance to this and other antibiotics at dialysis units.
Downloads
References
(1) Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D’Agata EM. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis. 2003;37(12):1629-38. DOI 10.1086/379715.
(2) Aguinaga A, Pozo JL. Infección asociada a catéter en hemodiálisis: diagnóstico , tratamiento y prevención. Nefrología. 2011;4(1):1-56. DOI 10.3265/NefroPlus.pre2011.Jun.11016.
(3) Peña C, Fernández-Sabe N, Domínguez MA, M Pujol, Martinez-Castelao A, Ayats J, et al. Staphylococcus aureus nasal carriage in patients on haemodialysis: role of cutaneous colonization. J Hosp Infect. 2004;58(1):20-7. DOI 10.1016/j.jhin.2004.04.018.
(4) Frank DN, Feazel LM, Bessesen MT, Price CS, Janoff EN, Pace NR. The human nasal microbiota and Staphylococcus aureus carriage. PLoS One. 2010;5(5):e10598. DOI 10.1371/journal.pone.0010598.
(5) Grothe C, Taminato M, Belasco A, Sesso R, Barbosa D. Screening and treatment for Staphylococcus aureus in patients undergoing hemodialysis: a systematic review and meta-analysis. BMC Nephrol. 2014;15:202. DOI 10.1186/1471-2369-15-202.
(6) Calfee DP. Multidrug-resistant organisms in dialysis patients. Semin Dial. 2013;26(4):447-56. DOI 10.1111/sdi.12094.
(7) Colombia. Ministerio de Salud y Protección Social. Guía para el manejo de la enfermedad renal crónica y Modelo de prevención y control de la enfermedad renal crónica Componente de un modelo de salud renal [Internet]. [Consultado 2018 sep 15]. Available from: https://bit.ly/2X8iSSi
(8) Nguyen DB, Lessa FC, Belflower R, Mu Y, Wise M, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections among patients on chronic dialysis in the United States, 2005-2011. Clin Infect Dis. 2013;57(10):1393-400. DOI 10.1093/cid/cit546.
(9) CDC. Centers for Disease Control and Prevention: Recommendations for preventing transmission of infections among chronic hemodialysis patients[Internet]. [Cited 2018 Sep 4]. Available from: https://bit.ly/2XDdvJU
(10) Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother. 2015;70(10):2681-92. DOI 10.1093/jac/dkv169.
(11) Yang JA, Park DW, Sohn JW, Yang IS, Kim KH, Kim MJ. Molecular analysis of isoleucyl-tRNA synthetase mutations in clinical isolates of methicillin-resistant Staphylococcus aureus with low-level mupirocin resistance. J Korean Med Sci. 2006;21(5):827-32. DOI 10.3346/jkms.2006.21.5.827.
(12) Khoshnood S, Heidary M, Asadi A, Soleimani S, Motahar M, Savari M, et al. A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against Staphylococcus aureus. Biomed Pharmacother. 2019;109:1809-18. DOI 10.1016/j.biopha.2018.10.131.
(13) Hetem DJ, Bonten MJ. Clinical relevance of mupirocin resistance in Staphylococcus aureus. J Hosp Infect. 2013;85(4):249-56. DOI 10.1016/j.jhin.2013.09.006.
(14) Clinical and Laboratory Standards Institute. Performance Standards For Antimicrobial Susceptibility Testing. EE.UU:CDC; 2018.
(15) Diseases I. Mupirocin Rationale for the EUCAST clinical breakpoints , version 1 . 0 Foreword [Internet]. [Cited 2018 Jul 11]. Available from: https://bit.ly/2zFa51g
(16) Ardanuy C, Cercenado E, Morosini MI, Torres C. Procedimientos en Microbiología Clínica. España: EIMC; 2011.
(17) Vázquez NM, Fiorilli G, Cáceres Guido C, Moreno S. Resistencia emergente a la mupirocina en aislados de Staphylococcus aureus resistente a meticilina en un hospital pediátrico terciario en la Argentina. Arch Argent Pediatr. 2019;117(1):48–52. DOI 10.5546/aap.2019.48.
(18) Jimenez N, Ocampo AM, Vanegas JM, Rodriguez EA, Mediavilla J, Restrepo AV, et al. CC8 MRSA strains harboring SCCmec type IVc are predominant in Colombian hospitals. PLoS One. 2012;7(6):e38576. DOI 10.1371/journal.pone.0038576.
(19) Watanabe H, Masaki H, Asoh N, Watanabe K, Oishi K, Furumoto A, et al. Emergence and spread of lowlevel mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan. J Hosp Infect. 2001;47(4):294-300. DOI 10.1053/jhin.2000.0931.
(20) Abad CL, Pulia MS, Safdar N. Does the nose know? An update on MRSA decolonization strategies. Curr Infect Dis Rep. 2013;15(6):455-64. DOI 10.1007/s11908-013-0364-y.
(21) van Rijen MM, Bonten M, Wenzel RP, Kluytmans JA. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. J Antimicrob Chemother. 2008;61(2):254-61. DOI 10.1093/jac/dkm480.
(22) García AM, Villa MV, Escudero ME, Gómez P, Vélez MM, Múnera MI, et al. Uso nasal de la mupirocina para Staphylococcus aureus: efecto en portadores y en infecciones nosocomiales. Biomédica. 2003;23(2). DOI 10.7705/biomedica.v23i2.1209.
(23) Boyce JM. MRSA patients: proven methods colonization and infection. J Hosp Infect. 2001;48(2001):9–14. DOI 10.1016/S0195-6701(01)90005-2.
(24) Gebreselassie HM, Lo Priore E, Marschall J. Effectiveness of meticillin-resistant Staphylococcus aureus decolonization in long-term haemodialysis patients: a systematic review and meta-analysis. J Hosp Infect. 2015;91(3):250-6. DOI 10.1016/j.jhin.2015.08.015.
(25) Gaona de Hernandez MA. Revista ciencias de la salud. Portadores Staphylococcus aureus como factor riesgo en la Infecc intrahospitalaria. Rev. Cienc. Salud. 2016;14(1):5–7.
(26) Ibeas J, Roca-Tey R, Vallespín J, Moreno T, Moñux G, Martí-Monrós A, et al. Guía Clínica Española del Acceso Vascular para Hemodiálisis. Nefrología. 2017;37:1–191. DOI 10.1016/j.nefro.2017.11.004.
(27) Dadashi M, Hajikhani B, Darban-Sarokhalil D, van Belkum A, Goudarzi M. Mupirocin resistance in Staphylococcus aureus: A systematic review and metaanalysis. J Glob Antimicrob Resist. 2020;20:238–47. DOI 10.1016/j.jgar.2019.07.032.
(28) Teo BW, Low SJ, Ding Y, Koh TH, Hsu LY. High prevalence of mupirocin-resistant staphylococci in a dialysis unit where mupirocin and chlorhexidine are routinely used for prevention of catheter-related infections. J Med Microbiol. 2011;60(Pt 6):865-7. DOI 10.1099/jmm.0.024539-0.
(29) Bettin A, Causil C, Reyes N. Molecular identification and antimicrobial susceptibility of Staphylococcus aureus nasal isolates from medical students in Cartagena, Colombia. Braz J Infect Dis. 2012;16(4):329-34. DOI 10.1016/j.bjid.2012.06.017.
(30) Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014;6:25-64. DOI 10.4137/PMC.S14459.
(31) OMS. ¿Qué es la resistencia a los antimicrobianos? [Internet]. Ginebra: OMS; c1999. [Cited 2018 Aug 25]. Available from: https://bit.ly/2XccEAJ
(32) Hidalgo M, Carvajal LP, Rincón S, Faccini-Martínez AA, Palacios AAT, Mercado M, et al. Methicillin-Resistant Staphylococcus aureus USA300 Latin American Variant in Patients Undergoing Hemodialysis and HIV Infected in a Hospital in Bogotá, Colombia. PLoS One. 2015;10(10):e0140748. DOI 10.1371/journal.pone.0140748.
(33) Kang YC, Tai WC, Yu CC, Kang JH, Huang YC. Methicillin-resistant Staphylococcus aureus nasal carriage among patients receiving hemodialysis in Taiwan: prevalence rate, molecular characterization and de-colonization. BMC Infect Dis. 2012;12:284. DOI 10.1186/1471-2334-12-284.
(34) Rodríguez Tamayo EA, Jiménez Quiceno JN. Factores relacionados con la colonización por Staphylococcus aureus. Iatreia. 2015;28(1):66–77.
(35) Rajkumari N, Mathur P, Bhardwaj N, Gupta G, Dahiya R, Behera R. Resistance pattern of mupirocin in methicillin-resistant Staphylococcus aureus in trauma patients and comparison between disc diffusion and E-test for better detection of resistance in low resource countries. J Lab Physicians. 2014;6(2):91-5. DOI 10.4103/0974-2727.141505.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Universidad de Antioquia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
